Company Overview and News

 
A 9% Yield, With 16 Straight Hikes, And Higher Guidance

2018-09-15 seekingalpha
This high-yield vehicle has returned more than 2X the S&P - it's up 10% for Hidden Dividend Stocks Plus members.
PBF PBFX

 
PBFX / PBF Logistics LP FORM S-3

2018-09-14 sec.gov
Form S-3 Table of Contents As filed with the Securities and Exchange Commission on September 14, 2018 Registration No. 333- &
PBFX

9
Beat The Recession With Dividends - Part 2

2018-09-05 seekingalpha - 3
It is almost impossible to find investments that would give $33,726 a year in dividends when only using $200,000-$300,000.
PBI GLOP VLP LB PBOWP PBOWN CGA HCLP HIHO PBI-B T MIC PBFX DMLP CVRR SALM

1
PBFX / PBF Logistics LP 8-K (Current Report)

2018-09-05 sec.gov - 1
Document UNITED STATES
PBFX

1
Buy PBF For The Margin Expansion And Discounted Valuation

2018-08-15 seekingalpha
PBF Energy (PBF) is a large independent oil refiner. The company has seen its earnings grow significantly in recent years on the back of M&A, organic capex projects, and margin improvement projects. Despite this, PBF’s stock trades at just 8.3x forward EV / EBIT while carrying a 2.5% dividend yield. Investors interested in refining stocks should consider PBF as it will likely continue growing earnings at an above-industry rate and currently trades at a discounted valuation multiple.
PBF KMI PBFX KMR KMRFZ CVB

 
PBF Logistics LP (PBFX) Q2 2018 Results - Earnings Call Transcript

2018-08-04 seekingalpha
PBF Logistics LP. (NYSE:PBFX) Q2 2018 Results Earnings Conference Call August 2, 2018 11:00 AM ET
PBFX

 
PBFX / PBF Logistics LP 8-K (Current Report)

2018-08-02 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
PBFX

 
PBFX / PBF Logistics LP 8-K (Current Report)

2018-08-02 sec.gov
Document UNITED STATES
PBFX

 
PBFX / PBF Logistics LP 8-K (Current Report)

2018-07-20 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
PBFX

19
89 Champions, Contenders, And Challengers Rank As Wall St. Dividend Stars For July

2018-07-19 seekingalpha
Champion dividend stocks sustain 25 or more annual dividend increases; Contenders show 10-24; Challengers have 5-9. WallStar selections all show .5% or higher price target upsides.
PM HMLP ETE GLOP ENB ANDX PBFX DKL SUN EBBNF MO ENBBF PEGI TLP NRZ SRLP ENB TCP ORI SIR PEG

 
PBFX / PBF Logistics LP 424B5 (Prospectus)

2018-07-17 sec.gov
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-207377 Prospectus Supplement (To Prospectus dated October 20, 2015)
PBFX

 
PBFX / PBF Logistics LP 8-K (Current Report)

2018-07-17 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
PBFX

1
PBFX / PBF Logistics LP 8-K (Current Report)

2018-06-19 sec.gov - 1
Document UNITED STATES
PBFX

35
90 Champions, Contenders And Challengers Are Wall Street Dividend Stars For June

2018-06-12 seekingalpha
Champion dividend stocks sustain 25 or more annual dividend increases; Contenders show 10 to 24; Challengers have 5 to 9. WallStar selections all show .7% or higher price target upsides.
PM HMLP ENB SEP ABRN PBFX DKL SUN PBF ABR TLP PEGI NRZ MDP SRLP ENB TCP ABRN.CL SIR PPL PEG

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

17h - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

17h - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

19h - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 69318Q104